Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.31 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.31 |
| ▸ | ITGAL | P20701 | 1/20 | 0.31 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7159681 | 0.88 | LMNA (0.33) | FFAR4NPC1CYP1A2CYP2C19RAB9A | |
| SCHEMBL372145 | 0.82 | ITGB2 (0.39) | NPC1RAB9ASMN1; SMN2ITGB2ICAM1 | |
| SCHEMBL19928557 | 0.81 | DRD1 (0.36) | NPC1RAB9ASMN1; SMN2ITGB2ICAM1 | |
| SCHEMBL3136613 | 0.79 | ITGB2 (0.39) | NPC1RAB9ASMN1; SMN2ITGB2ICAM1 | |
| SCHEMBL9913796 | 0.78 | DRD1 (0.36) | SMN1; SMN2ITGB2ICAM1ITGALMAP3K14 | |
| SCHEMBL20351197 | 0.78 | ITGB2 (0.38) | NPC1RAB9ASMN1; SMN2ITGB2ICAM1 | |
| SCHEMBL13243539 | 0.78 | ITGB2 (0.38) | NPC1RAB9ASMN1; SMN2ITGB2ICAM1 | |
| SCHEMBL3133241 | 0.78 | ITGB2 (0.38) | NPC1RAB9ASMN1; SMN2ITGB2ICAM1 | |
| SCHEMBL14692659 | 0.76 | NR3C1 (0.31) | — | |
| SCHEMBL3132985 | 0.75 | ITGB2 (0.46) | SMN1; SMN2ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169600-A1 | METHOD FOR PRODUCING PKROSTAGLANDIN | KYOWA PHARMA CHEMICAL CO., LTD. (JP) | 2022-06-02 | — | — | US | disclosed |
| US-9896402-B2 | Method for preventing decrease in optical purity | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2018-02-20 | — | — | US | disclosed |
| EP-2774908-B1 | METHOD FOR PREVENTING DECREASE IN OPTICAL PURITY | TAKASAGO PERFUMERY CO LTD (JP) | 2017-02-08 | — | — | EP | disclosed |
| US-9328079-B2 | Process for producing optically active amine | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-05-03 | — | — | US | disclosed |
| US-9255049-B2 | Ruthenium complex and method for preparing optically active alcohol compounds using the same as a catalyst | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-02-09 | — | — | US | disclosed |
| US-20150210657-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE AMINE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-07-30 | — | — | US | disclosed |
| US-9079931-B2 | Ruthenium complex and method for preparing optically active alcohol compound | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-07-14 | — | — | US | disclosed |
| US-20140296582-A1 | METHOD FOR PREVENTING DECREASE IN OPTICAL PURITY | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2014-10-02 | — | — | US | disclosed |
| EP-2774908-A1 | METHOD FOR PREVENTING DECREASE IN OPTICAL PURITY | Takasago International Corporation (JP) | 2014-09-10 | — | — | EP | disclosed |
| US-20140187809-A1 | NOVEL RUTHENIUM COMPLEX AND PROCESS FOR PRODUCING OPTICALLY ACTIVE ALCOHOL COMPOUND USING SAME AS CATALYST | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2014-07-03 | — | — | US | disclosed |
| EP-2695887-A1 | NOVEL RUTHENIUM COMPLEX AND PROCESS FOR PRODUCING OPTICALLY ACTIVE ALCOHOL COMPOUND USING SAME AS CATALYST | Takasago International Corporation (JP) | 2014-02-12 | — | — | EP | disclosed |
| US-20130041151-A1 | RUTHENIUM COMPLEX AND METHOD FOR PREPARING OPTICALLY ACTIVE ALCOHOL COMPOUND | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-02-14 | — | — | US | disclosed |
| EP-1095946-B1 | Optically active diphosphine compound, production intermediates therefor, transition metal complex containing the compound as ligand and asymmetric hydrogenation catalyst containing the complex | TAKASAGO PERFUMERY CO LTD (JP) | 2003-08-27 | — | — | EP | disclosed |
| US-6333291-B1 | USEFUL AS A LIGAND OF CATALYSTS FOR ASYMMETRIC SYNTHESIS REACTIONS SUCH AS ASYMMETRIC HYDROGENATION REACTION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2001-12-25 | — | — | US | disclosed |
| EP-1095946-A1 | Optically active diphosphine compound, production intermediates therefor, transition metal complex containing the compound as ligand and asymmetric hydrogenation catalyst containing the complex | Takasago International Corporation (JP) | 2001-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296582-A1 | METHOD FOR PREVENTING DECREASE IN OPTICAL PURITY | QDPR, NOX4, NOX5 | FFAR4 4210/4885NPC1 469/4885CYP1A2 2932/4885 |
| US-20220169600-A1 | METHOD FOR PRODUCING PKROSTAGLANDIN | PTGS1, PTGER1, RACK1 | FFAR4 1604/4885NPC1 2818/4885CYP1A2 472/4885 |
| US-20130041151-A1 | RUTHENIUM COMPLEX AND METHOD FOR PREPARING OPTICALLY ACTIVE ALCOHOL COMPOUND | ADH5, ADH1C, ADH1A | FFAR4 2018/4885NPC1 3522/4885CYP1A2 23/4885 |
| US-20140187809-A1 | NOVEL RUTHENIUM COMPLEX AND PROCESS FOR PRODUCING OPTICALLY ACTIVE ALCOHOL COMPOUND USING SAME AS CATALYST | ADH1C, ADH5, ADH1A | FFAR4 1775/4885NPC1 3755/4885CYP1A2 37/4885 |
| US-20150210657-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE AMINE | HRH3, HRH1, ATIC | FFAR4 3210/4885NPC1 3125/4885CYP1A2 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.